A Study of ASN007 in Patients With Advanced Solid Tumors
The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.
A Phase 1, Open-Label, Dose-Finding Study of ASN007 in Patients with Advanced Solid Tumors
- ClinicalTrials.gov Identifier: NCT03415126
- Protocol Number: 18-228
- Principal Investigator: Glen Weiss
- Principal Investigator: Central PIO
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required